We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Renal Cell Carcinoma

Journal Scan / Research · March 25, 2021

Combination Antiangiogenic TKI/ICI Therapy in Metastatic Renal Cell Carcinoma

Cancer Medicine


Additional Info

Disclosure statements are available on the authors' profiles:

Cancer Medicine
Combination Antiangiogenic Tyrosine Kinase Inhibition and Anti-PD1 Immunotherapy in Metastatic Renal Cell Carcinoma: A Retrospective Analysis of Safety, Tolerance, and Clinical Outcomes
Cancer Med 2021 Apr 01;10(7)2341-2349, AL Laccetti, B Garmezy, L Xiao, M Economides, A Venkatesan, J Gao, E Jonasch, P Corn, A Zurita-Saavedra, LC Brown, C Kao, EN Kinsey, RT Gupta, MR Harrison, AJ Armstrong, DJ George, N Tannir, P Msaouel, A Shah, T Zhang, MT Campbell

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading